

Table of Contents

1.0 INTRODUCTION	1	5.2 Challenges of Using Comparability Assessments for Vaccines	13
1.1 Purpose	2	5.3 Recommended Considerations for Comparability Protocols and Comparability Assessments for Vaccines	14
1.2 Scope	3	5.4 Suggested Best Practices for Comparability Assessments.....	16
2.0 ABBREVIATIONS	4		
3.0 EXISTING GUIDANCE DOCUMENTS FOR VACCINES...	4		
4.0 CONTROL STRATEGY FROM PROCESS DEVELOPMENT TO VACCINE LIFECYCLE MANAGEMENT	6	6.0 CONSIDERATIONS FOR VACCINES LIFECYCLE MANAGEMENT	19
4.1 Key Elements and Considerations for Establishing Vaccines Control Strategy.....	6	6.1 Nonregulatory Considerations for Management of Post-Approval Changes	20
4.2 Considerations for Setting and Managing Vaccine Specifications	7	6.1.1 Technical Considerations for Management of Changes	20
4.2.1 Considerations for Setting Vaccine Specifications: Critical Quality Attributes and Ranges	7	6.1.2 Validation Considerations for Management of Changes	26
4.2.2 Approaches for Analytical Procedures Selection in Specifications	9	6.1.3 Relying on Effective Pharmaceutical Quality System for Management of Changes.....	29
4.2.3 Managing Vaccine Specifications throughout Product Lifecycle.....	10	6.1.4 Use of a Risk-Based Approach and Development of an Effective PQS.....	29
4.3 Establishing Process Parameter Classifications and Lifecycle Management	10	6.2 Regulatory Considerations for Management of Post-Approval Changes	30
4.3.1 Considerations for Establishing Process Parameter Classifications.....	10	6.2.1 General Regulatory Considerations for Management of PACs.....	31
4.3.2 Considerations for Reclassification of Parameters	11	6.2.2 Key Considerations for Post-Approval Change Submissions.....	32
5.0 COMPARABILITY ASSESSMENTS: ENABLER FOR CHANGES DURING DEVELOPMENT AND AFTER APPROVAL	12	6.2.3 Using the Regulatory Mechanism of ICH Q12.....	33
5.1 Benefits of Comparability Protocols and Comparability Exercises for Vaccines.....	12	6.2.4 Strategies for Multinational and Multiproduct Submissions	36
		7.0 CONCLUSION	37
		8.0 REFERENCES	38

FIGURES AND TABLES INDEX

Figure 1.0-1 Complexity of Vaccine Development and Lifecycle Management.....	1	Table 5.2-1 Examples where Vaccine Changes Could be Justified with Analytical or Target Clinical Data	14
Table 1.0-1 Diversity in Vaccine Platforms	2	Table 5.3-1 Examples of Quality Attributes that Could Leverage Analytical Comparability.....	15
Table 3.0-1 Summary of Selected Guidance and Industry Documents and Relevance to Strategies for Vaccines Development and Lifecycle Management	5	Table 5.3-2 Examples where Comparability could be Considered without Need for Additional Clinical Studies.....	15
Figure 4.1-1 Holistic Control Strategy for Vaccines Development and Lifecycle	6	Table 5.3-3 Examples when Clinical Data may be Required to Support Comparability.....	16
Table 4.2.1-1 Examples of Quality Attributes with Additional Considerations for Vaccines.....	8	Table 5.4-1 Practical Considerations for Comparability Assessments	16
Table 4.3.2-1 Examples of Parameter Classification Changes	11	Figure 5.4-2 Timing of Implementation Using	

	Comparability Protocol	18	Table 6.1.2.3-1	Matrix Approach using Three Strategies	27
Table 5.4-2	Common Comparability Protocols Received by U.S. FDA, 2004-2014.....	18	Figure 6.1.2.3-1	Representation of Matrix Validation Approach	28
Figure 6.0-1	Representation of the Complexity in Managing Multinational Regulatory Submissions.....	19	Table 6.1.2.3-2	Illustration of a Matrix Approach for Filling Process PPQ	28
Figure 6.0-2	Vaccine Inventory Complexity Management	20	Figure 6.1.4-1	Risk-Based Assessment of PACs and Determination of Regulatory Reporting Category	30
Figure 6.1-1	Vaccine Lifecycle Management Complexity.....	21	Table 6.2.1-1	Overview of the Current Situation and Proposals for Improvement.....	32
Table 6.1.1.2-1	Examples of Working Cell Bank Manufacturing Changes, Potential Classification, and Supporting Data Expectations	23	Figure 7.0-1	Key Elements to Consider during Development of a Vaccine Strategy.....	38